EUCTR2005-004434-40-BE进行中（未招募）不适用
A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and Seretide 50/500mcg alone) in the treatment of subjects with COPD
GlaxoSmithKline Research and Development Ltd0 个研究点目标入组 48 人开始时间: 2006年2月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1.Male or female aged 40 - 80 years inclusive
- •2.Has an established clinical history of COPD (defined as per the GOLD definition which defines COPD as characterised by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases)
- •3.A signed and dated written informed consent is obtained from the subject prior to study participation
- •4.The subject has a post-bronchodilator FEV1 of >30% to ? 75% of predicted normal at Visit 1
- •5.The subject has a post-bronchodilator FEV1 / FVC ratio = 70% at Visit 1
- •6.The subject achieves a score of ? 2 on the Modified Medical Research Council (MRC) Dyspnoea Scale at Visit 1
- •7.The subject is a current or ex-smoker with a smoking history of > 10 pack-years (10 pack years is defined as 20 cigarettes per day for 10 years, or 10 cigarettes (or equivalent if subject smoked cigars or a pipe) per day for 20 years). Ex smokers are required to have stopped smoking for at least 6 months prior to visit 1. Ex-smokers who stopped smoking less than 6 months ago will be defined as current smokers.
- •8.A female is eligible to enter this study if she is:
- •aof non-childbearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal), or
- •bof child-bearing potential, but has a negative urinary pregnancy test at screening and agrees to take contraceptive precautions (including abstinence) which are adequate to prevent pregnancy during the study
- •cnot a nursing mother
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •1.Has had a COPD exacerbation within the 4 weeks prior to Visit 1 (See Section 6.3.1)
- •2.Had any changes in COPD medication in the 4 weeks prior to Visit 1
- •3.Has a current medical diagnosis of asthma and/or allergic rhinitis
- •4.Has a medical diagnosis of narrow-angle glaucoma, prostatic hyperplasia or bladder neck obstruction that in the opinion of the investigator should prevent them from entering the study
- •Note: As with other anticholinergic drugs, subjects with narrow-angle glaucoma, prostatic hyperplasia or bladder neck obstruction should only be entered into the study at the Investigator’s discretion
- •5.Has known respiratory disorders other than COPD (e.g. lung cancer, sarcoidosis, tuberculosis or lung fibrosis)
- •6.Has undergone lung surgery e.g., lung transplant and/or lung volume reduction
- •7.Is currently receiving pulmonary rehabilitation
- •8.Had a chest X-ray indicating diagnosis other than COPD that might interfere with the study (chest X-ray to be taken at entry to the run-in period, if subject has not had one taken within 3 months of Visit 1)
- •9.Requires regular (daily) or long term oxygen therapy (LTOT). (LTOT is defined as ? 12 hours oxygen use per day)
- •10.Requires regular treatment with oral, parenteral, or depot corticosteroids or has received 2 or more periods of oral corticosteroids for COPD exacerbation in the last 6 months
- •11.Received oral, parenteral, or depot corticosteroids in the 4 weeks prior to Visit 1
- •12.Received antibiotic therapy for either a lower respiratory tract infection or for COPD exacerbation within the 8 weeks prior to Visit 1
- •13.Has been hospitalised for a COPD exacerbation in the last year
- •14.Receiving ?-blockers (except eye drops)
- •15.Has serious, uncontrolled disease likely to interfere with the study (e.g. Left Ventricular failure, anaemia, renal or hepatic disease or serious psychological disorders)
- •16.Received any other investigational drugs within 4 weeks (or 5 half lives) prior to Visit 1
- •17.Has, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse
- •18.Has a known or suspected hypersensitivity to ß2-agonists, inhaled steroids, anticholinergic treatments or any components of the formulations (e.g. lactose or milk protein)
- •19.Has previously been enrolled to this study
- •20.Subjects who are not considered able to tolerate three 2-weeks wash-out periods according to the study schedule with all COPD medications removed apart from rescue use of VENTOLIN via MDI or DISKUS (inhaled PRN use).
研究者
相似试验
进行中（未招募）
1 期
A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and Seretide 50/500mcg alone) in the treatment of subjects with COPDCOPDEUCTR2005-004434-40-GBGlaxoSmithKline Research and Development Ltd
已完成
不适用
A double-blind, randomized, controlled, 3-way crossover, pilot study to evaluate the duration of effects on simulated car driving and cognitive performance after a single dose of JNJ-42847922, zolpidem and placebo in healthy subjects10040991InsomniaDepressionNL-OMON42615Janssen-Cilag36
招募中
3 期
A phase 3, randomised, double-blind, double dummy, parallel group, multi-centre, multi-national study for evaluation of efficacy and safety of du-176b verses warfarin in subjects with atrial fibrillatioCardiovascular - Normal development and function of the cardiovascular systemCardiovascular - Coronary heart diseaseAtrial FibrillationACTRN12609000132246Daiichi Sankyo Pharma Development16,500
进行中（未招募）
不适用
ate development study which compares the effectiveness and safety of a not yet approved drug called edoxaban versus a widely-used andapproved drug called warfarin in patients suffering from blood clots inlegs and/or in lungs. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving) and is being conducted in many countries around the worldReduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)MedDRA version: 14.1Level: PTClassification code 10037377Term: Pulmonary embolismSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 14.1Level: PTClassification code 10051055Term: Deep vein thrombosisSystem Organ Class: 10047065 - Vascular disordersEUCTR2009-014290-40-EEDaiichi Sankyo Development Limited7,500
进行中（未招募）
1 期
A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis and/or pulmonary embolism - Evaluation of edoxaban vs. warfarin in subjects with symptomatic venous thromboembolism (VTE)Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)MedDRA version: 12.0Level: LLTClassification code 10037377Term: Pulmonary embolismMedDRA version: 12.0Level: LLTClassification code 10051055Term: Deep vein thrombosisEUCTR2009-014290-40-FRDaiichi Sankyo Development Limited7,500